MediciNova Announces Phase 3 Clinical Trial Plan for MN-166 (ibudilast) in Progressive MS

World News: . []

LA JOLLA Calif July 11 2019 GLOBE NEWSWIRE -- MediciNova Inc a biopharmaceutical company LINK  on the NASDAQ Global LINK  NASDAQMNOV and the JASDAQ Market of the Tokyo Stock Exchange Code LINK  4875 today announced its plans for a Phas...

More news and information about MediciNova, Inc.

Published By:

Globe Newswire: 00:00 GMT Friday 12th July 2019

Published: .

Search for other references to "medicinova" on SPi News


Share

Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2020. [Admin Only]
 
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 07519380.
 
Privacy Policy | Terms and Conditions | Contact Us